The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
Abstract
The clinical features of relapses and progression largely define multiple sclerosis phenotypes. A relapsing course is followed by chronic progression in some 80% of cases within 2 decades. The relationship between these phases and long-term outcome remains uncertain. We have analysed these clinical features within a well-studied natural history cohort with mean follow-up of 25 years. For the entire cohort, median times to reach Disability Status Scale (DSS) 6, 8 and 10 were 12.7, 20.6 and 43.9 years, respectively. Among 824 attack-onset patients, the great majority entered a progressive phase with a mean time to progression of 10.4 years. The effects of relapses often cloud the clinical onset of progression. However, there are circumstances where onset of progression is early, relatively discrete and identifiable at DSS of 2 or less. Three subgroups allow for clarity of outcome comparison and they are (i) cases of primary progressive (PP) disease, (ii) attack-onset disease where only a single attack has occurred before onset of progression (SAP) and (iii) secondary progressive (SP) disease where recovery from relapses allows recognition of the earliest clinical stages when progression begins. Here we compare survival curves in these three groups. Among cohorts of SAP (n = 140), PP (n = 219) and SP (n = 146) where progression was stratified by DSS at its onset, there was no difference in time to DSS 6, 8 and 10. These findings demonstrate that the progressive course is independent of relapses either preceding the onset of relapse-free progression or subsequent to it. Among SAP patients, the degree of recovery from the single defining exacerbation had no significant effect on outcome. The site of the original attack was not usually where progression began. The relatively stereotyped nature of the progressive phase seen in all progressive phenotypes suggests regional and/or functional differential susceptibility to a process that appears degenerative in nature. The highly prevalent distal corticospinal tract dysfunction in progressive disease and the pathologically demonstrated selective axonal loss seen in this tract raises the possibility of a dying back central axonopathy, at least in part independent of plaque location or burden. Despite considerable individual variation, the progressive course of disability seen in groups of PP, SAP and SP-DSS2 is similarly stereotyped in quality and pace and may entail mechanisms common to all forms of progressive multiple sclerosis. The possibility that this is the primary process in some cases must be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Self-citationAxonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Self-citationJohnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
The clinical course of neuromyelitis optica (Devic’s syndrome)
Wingerchuk, D. M., Hogancamp, W. F., O’Brien, P. C., & Weinshenker, B. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1107 · Cited by 1,822
Self-citationAxonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Self-citationSchumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., Nagler, B., Sibley, W. A., Tourtellotte, W. W., & Willmon, T. L. (1965) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb20235.x · Cited by 1,438
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
Self-citationConfavreux, C. (2003) · Brain · doi:10.1093/brain/awg081 · Cited by 996
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 916
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.6.1419 · Cited by 602
Self-citationPrognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up
Runmarker, B., & Andersen, O. (1993) · Brain · doi:10.1093/brain/116.1.117 · Cited by 568
Primary progressive multiple sclerosis
Thompson, A. (1997) · Brain · doi:10.1093/brain/120.6.1085 · Cited by 506
CONFAVREUX, C., AIMARD, G., & DEVIC, M. (1980) · Brain · doi:10.1093/brain/103.2.281 · Cited by 494
Anatomie pathologique du corps humain
Cruveilhier, J. (1829) · Institutional Repository University of Antioquia (University of Antioquia) · Cited by 430
WEINSHENKER, B. G., RICE, G. P. A., NOSEWORTHY, J. H., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1991) · Brain · doi:10.1093/brain/114.2.1045 · Cited by 401
Self-citationOn the evaluation of disability in multiple sclerosis
Kurtzke, J. F. (1961) · Neurology · doi:10.1212/wnl.11.8.686 · Cited by 330
THE NEUROPATHOLOGY OF MULTIPLE SCLEROSIS
Ludwin, S. K. (2000) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(25)00665-3 · Cited by 329
Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
Rice, G. P. A., Filippi, M., Comi, G., & for the Cladribine Clinical Study Group and for the Cladribine MRI Study Group* (2000) · Neurology · doi:10.1212/wnl.54.5.1145 · Cited by 325
Self-citationComparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis
Lassmann, H. (1983) · Schriftenreihe Neurologie / Neurology Series · doi:10.1007/978-3-642-45558-2 · Cited by 296
Hawkins, S. A., & McDonnell, G. V. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.2.148 · Cited by 260
Behçet's disease and the nervous system
Serdaroğlu, P. (1998) · Journal of Neurology · doi:10.1007/s004150050205 · Cited by 258
Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts
DeLuca, G. C. (2004) · Brain · doi:10.1093/brain/awh118 · Cited by 255
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
Rudick, R. A., Goodkin, D. E., Jacobs, L. D., Cookfair, D. L., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Granger, C. V., Simon, J. H., et al. (1997) · Neurology · doi:10.1212/wnl.49.2.358 · Cited by 232
The extent of axonal loss in the long tracts in hereditary spastic paraplegia
DeLuca, G. C., Ebers, G. C., & Esiri, M. M. (2004) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2004.00587.x · Cited by 194
Self-citationMoreau, T., Scolding, N., Compston, A., Thorpe, J., Miller, D., Moseley, I., Hale, G., Waldmann, H., Clayton, D., Wing, M., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91339-0 · Cited by 187
Age‐related disability in multiple sclerosis
Trojano, M., Liguori, M., Bosco Zimatore, G., Bugarini, R., Avolio, C., Paolicelli, D., Giuliani, F., De Robertis, F., Marrosu, M. G., & Livrea, P. (2002) · Annals of Neurology · doi:10.1002/ana.10147 · Cited by 186
The natural history of multiple sclerosis: a geographically based study
Kremenchutzky, M., Cottrell, D., Rice, G., Hader, W., Baskerville, J., Koopman, W., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.10.1941 · Cited by 186
Self-citationWEINSHENKER, B. G., RICE, G. P. A., NOSEWORTHY, J. H., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1991) · Brain · doi:10.1093/brain/114.2.1057 · Cited by 175
Self-citationBornstein, M. B., Miller, A., Slagle, S., Weitzman, M., Drexler, E., Keilson, M., Spada, V., Weiss, W., Appel, S., Rolak, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.533 · Cited by 173
Studies on the natural history of multiple sclerosis—8
Kurtzke, J. F., Beebe, G. W., Nagler, B., Kurland, L. T., & Auth, T. L. (1977) · Journal of Chronic Diseases · doi:10.1016/0021-9681(77)90010-8 · Cited by 165
The Danish Multiple Sclerosis Registry: a 50-year follow-up
Koch‐Henriksen, N. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500418 · Cited by 157
Ebers, G. C., Koopman, W. J., Hader, W., Sadovnick, A. D., Kremenchutzky, M., Mandalfino, P., Wingerchuk, D. M., Baskerville, J., & Rice, G. P. (2000) · Brain · doi:10.1093/brain/123.3.641 · Cited by 147
Self-citationAge at onset and different types of psoriasis
Swanbeck, G., Inerot, A., Martinsson, T., et al. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb02753.x · Cited by 140
Patzold, U., & Pocklington, P. R. (1982) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1982.tb03084.x · Cited by 121
STUDIES ON THE NATURAL HISTORY OF MULTIPLE SCLEROSIS
Nagler, B., Beebe, G. W., Kurtzke, J. F., Kurland, L. T., Auth, T. L., & Nefzger, M. D. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1966.tb02012.x · Cited by 107
TOPOGRAPHIC DISTRIBUTION OF PLAQUES IN THE SPINAL CORD IN MULTIPLE SCLEROSIS
Fog, T. (1950) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1950.02310210028003 · Cited by 106
The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis
Noseworthy, J. H., O’Brien, P. C., Erickson, B. J., Lee, D. D., Sneve, D., Ebers, G. C., Rice, G. P. A., Auty, A., Hader, W. J., Kirk, A., et al. (1998) · Neurology · doi:10.1212/wnl.51.5.1342 · Cited by 97
Self-citationGenetic epidemiology of rheumatoid arthritis.
Lynn, A., Kwoh, C. K., Venglish, C. M., Aston, C. E., & Chakravarti, A. (1995) · PubMed Central · Cited by 88
Liu, C., & Blumhardt, L. D. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.4.450 · Cited by 86
Classification of the neuronal ceroid‐lipofuscinoses: Expansion of the atypical forms
Dyken, P. R., & Wisniewski, K. E. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320570208 · Cited by 84
Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada
Hader, W. J., Elliot, M., & Ebers, G. C. (1988) · Neurology · doi:10.1212/wnl.38.4.617 · Cited by 81
Self-citationVerjans, E., Theys, P., Delmotte, P., & Carton, H. (1983) · Journal of Neurology · doi:10.1007/bf00313739 · Cited by 48
A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis
van Oosten, B. W., Lai, M., Barkhof, F., Miller, D., MOSELEY, I. F., Thompson, A. J., Hodgkinson, S. J., & Polman, C. H. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600100611 · Cited by 32
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Cited by
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
Primary-progressive multiple sclerosis
Miller, D. H., & Leary, S. M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70243-0 · Cited by 818
Metadata
- Authors
- Kremenchutzky, M., Rice, G. P. A., Baskerville, J., Wingerchuk, D. M., & Ebers, G. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-01-09
- Volume
- 129
- Issue
- 3
- Pages
- 584-594
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2146853725
- Cited by
- 447
- References
- 54
- FWCI
- 16.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.